CS Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
J Virol. 2023 Dec 21;97(12):e0187022. doi: 10.1128/jvi.01870-22. Epub 2023 Nov 22.
Twenty-five years after the first report that HIV-2 infection can reduce HIV-1-associated pathogenesis in dual-infected patients, the mechanisms are still not well understood. We explored these mechanisms in cell culture and showed first that these viruses can co-infect individual cells. Under specific conditions, HIV-2 inhibits HIV-1 through two distinct mechanisms, a broad-spectrum interferon response and an HIV-1-specific inhibition conferred by the HIV-2 TAR. The former could play a prominent role in dually infected individuals, whereas the latter targets HIV-1 promoter activity through competition for HIV-1 Tat binding when the same target cell is dually infected. That mechanism suppresses HIV-1 transcription by stalling RNA polymerase II complexes at the promoter through a minimal inhibitory region within the HIV-2 TAR. This work delineates the sequence of appearance and the modus operandi of each mechanism.
首例报告指出,HIV-2 感染可降低双重感染患者的 HIV-1 相关发病机制,25 年后,其机制仍未得到充分理解。我们在细胞培养中探索了这些机制,首先发现这些病毒可以共同感染单个细胞。在特定条件下,HIV-2 通过两种不同的机制抑制 HIV-1,一种是广谱干扰素反应,另一种是由 HIV-2 TAR 赋予的 HIV-1 特异性抑制。前者可能在双重感染个体中发挥重要作用,而后者则通过竞争相同靶细胞的 HIV-1 Tat 结合来抑制 HIV-1 启动子活性。当 HIV-2 TAR 内的最小抑制区域使 HIV-1 转录物聚合酶 II 复合物在启动子处停滞时,该机制通过阻止 HIV-1 转录。这项工作描绘了每个机制出现的顺序和操作方式。